ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

enzomenib

Also written as “DSP-5336” and “Enzomenib”.

Its studies are mostly in Leukemia, Myeloid, Acute, led by Sumitomo Pharma.

Drug pageEnzomenib: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jul 26, 20212 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sumitomo Pharma21 open or runningphase 2since Jul 26, 2021Jul 26, 2021Jun 30, 2027phase 2 · NCT04988555

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 26, 2021First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT04988555 · 606 planned · United States, Belgium, Canada and more
  2. Feb 29, 2024Named enzomenibINNProposed as its International Nonproprietary Name in WHO's List 130 · before, DSP-5336
  3. Feb 6, 2026Phase 1 study in Advanced Hematologic MalignanciesNCT07444268 · 8 enrolled · United States

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT04988555

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07444268Advanced Hematologic Malignancies · United States1CompletedAug 11, 20268
NCT04988555Leukemia, Myeloid, Acute · United States, Belgium, Canada and more2RecruitingJun 30, 2027606

How it is read

Names in the registry

  • “DSP-5336”, 1 entry
  • “Enzomenib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.